Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KappaMab with or without lenalidomide and dexamethasone for relapsed/refractory kappa-restricted multiple myeloma
ACTRN12616001164482Phase 2Completed
- Sponsor
- The Alfred Hospital
- Start
- Nov 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of MDX-1097, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by The Alfred Hospital. Primary endpoint: Clinical benefit rate. Started Nov 2016; status: completed.
02
Drugs
MDX-1097lenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12616001164482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001164482.